Summit Corp. forms advisory board to aid development of drug

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD). The board will be made up of six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly DMD."We are absolutely delighted to have brought together these eminent thought leaders in neuromuscular diseases to form a world-class Advisory Board that will support our DMD programme," commented Glyn Edwards, Chief Executive Officer of Summit. "Their expertise brings a deep insight into the disease and will provide invaluable input into future patient clinical trials to support the progression of our utrophin modulation programme, including our lead candidate SMT C1100."Shares in the company have fallen almost 30% in the year-to-date, equal to 1.88p. NR